- Home
- STRS vs CMPX Comparison
STRS vs CMPX Comparison
Compare STRS & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRS
- CMPX
- Stock Information
- Founded
- STRS 1992
- CMPX 2014
- Country
- STRS United States
- CMPX United States
- Employees
- STRS N/A
- CMPX N/A
- Industry
- STRS Homebuilding
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- STRS Real Estate
- CMPX Health Care
- Exchange
- STRS Nasdaq
- CMPX Nasdaq
- Market Cap
- STRS 218.2M
- CMPX 214.6M
- IPO Year
- STRS N/A
- CMPX N/A
- Fundamental
- Price
- STRS $18.78
- CMPX $2.92
- Analyst Decision
- STRS
- CMPX Strong Buy
- Analyst Count
- STRS 0
- CMPX 6
- Target Price
- STRS N/A
- CMPX $12.50
- AVG Volume (30 Days)
- STRS 5.8K
- CMPX 1.4M
- Earning Date
- STRS 03-27-2025
- CMPX 03-20-2025
- Dividend Yield
- STRS N/A
- CMPX N/A
- EPS Growth
- STRS N/A
- CMPX N/A
- EPS
- STRS 0.19
- CMPX N/A
- Revenue
- STRS $48,157,000.00
- CMPX $850,000.00
- Revenue This Year
- STRS N/A
- CMPX N/A
- Revenue Next Year
- STRS N/A
- CMPX $613.39
- P/E Ratio
- STRS $97.31
- CMPX N/A
- Revenue Growth
- STRS 83.12
- CMPX N/A
- 52 Week Low
- STRS $18.11
- CMPX $0.77
- 52 Week High
- STRS $30.66
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- STRS 37.15
- CMPX 48.30
- Support Level
- STRS $18.22
- CMPX $3.14
- Resistance Level
- STRS $20.66
- CMPX $3.85
- Average True Range (ATR)
- STRS 0.55
- CMPX 0.33
- MACD
- STRS 0.00
- CMPX -0.11
- Stochastic Oscillator
- STRS 21.71
- CMPX 5.68
About STRS Stratus Properties Inc.
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.